Maraviroc treatment dampens peripheral T-cell activation. (A) CD38 expression by MFI on CD4⁺ T cells at day 30 and day 60 in control and maraviroc-treated patients. (B) Percentage of CD38⁺ cells among CD4⁺ T cells as measured by flow cytometry. (C) CD38 expression by MFI on CD8⁺ T cells at day 30 and day 60 in control and maraviroc-treated patients. (D) Percentage of CD38⁺ cells among CD8⁺ T cells. (E) HLA-DR expression by MFI on CD8⁺ T cells at day 30 and day 60. (F) Percentage of HLA-DR⁺ cells among CD8⁺ T cells at day 30 and day 60. *P < .05, **P < .01, Student t test.